References
- Cazzaniga ME, Dogliotti L, Cascinu S, Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter Study. Oncology 2006;71:374-381
- Body J, Diel IJ, Lichinitser MR, Intravenous ibandronic acid reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 2003;14:1399-1405
- Cameron Fallon M, Diel I. Ibandronic acid: its role in metastatic breast cancer. Oncologist 2006;11(Suppl 1):27-33
- Cameron D. Patient management issues in metastatic bone disease. Semin Oncol 2004;31:79-82
- Aapro M, Abrahamsson PA, Body JJ, Guidance on the use of bisphosphonates in solid tumours: recommendation of an international expert panel. Ann Oncol 2008;19:420-432
- Pecherstorfer M. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. Expert Opin Pharmacother 2008;9:3111-3119
- Corso A, Zappasodi P, Lazzarino M. Urinary proteins and renal dysfunction in patients with multiple myeloma. Biomed Pharmacother 2002;56:139-143
- Kintzel PE. Anticancer drug-induced kidney disorders. Drug Safety 2001;24:19-38
- McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 2006;66:711-728
- Munier A, Gras V, Andrejak M, Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-1197
- Johnson KB, Gable P, Kaime EM, Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 2003;22:738 (Abstr 2968)
- Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679
- Novartis Pharmaceuticals. Summary of Product Characteristics, Zometa 4 mg/5 ml concentrate for solution for infusion, 19 January 2009
- Pecherstorfer M, Rivkin S, Body JJ, Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer an open-label trial. Clin Drug Invest 2006;26:315-322
- McLachlan SA, Cameron D, Murray R, . Safety of oral ibandronate in the treatment of bone metastases from breast cancer. Clin Drug Invest 2006;26:43-48
- Roche Products Ltd. Summary of Product Characteristics, Bondronat 50 mg tablets, 25 September 2007
- Ibid
- NHS Reference costs 2006-2007. Available at: http://www.dh. gov.uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH_082571 (accessed 18.1.10)
- Serum creatinine. Available at: http://www.RNCEUS.com/renal/renalcreat.html (accessed 18.1.10)
- Schmidt M, Seraphin J, Luhn B, Soeling U. Renal safety and sustained bone pain effectiveness of ibandronate in breast cancer patients with metastatic bone disease: interim results of a non-interventional study in Germany. ePoster presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas, USA, December 10-14, 2008
- Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
- Body J, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005;10(Suppl 1):3-7